Novartis Ag (NVS) Income towards Parent Company (2009 - 2026)
Novartis Ag's (NVS) quarterly Income towards Parent Company came in at $3.3 billion in Q2 2026, down 19.23% year-over-year from $4.0 billion in Q2 2025, and down 27.82% quarter-over-quarter from $4.5 billion in Q1 2026.
Analysis
Novartis Ag (NVS) Income towards Parent Company (2009 - 2026) Analysis & Trends
Novartis Ag has disclosed Income towards Parent Company across 18 years of filings, most recently posting $3.3 billion for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 19.23% year-over-year to $3.3 billion; the TTM figure through Jun 2026 stood at $22.5 billion (down 7.91% YoY), while the FY2025 annual figure was $14.0 billion, up 17.11% from the prior year.
- Income towards Parent Company came in at $3.3 billion for Q2 2026 at Novartis Ag, down from $4.5 billion in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $13.4 billion in Q4 2023 to a low of $1.7 billion in Q2 2022.
- Average Income towards Parent Company over 5 years is $4.9 billion, with a median of $3.6 billion recorded in 2024.
- Year-over-year, Income towards Parent Company sank 59.69% in 2022 and surged 94.73% in 2024.
- Over 5 years, Income towards Parent Company stood at $7.2 billion in 2022, then soared by 85.16% to $13.4 billion in 2023, then declined by 13.5% to $11.6 billion in 2024, then decreased by 11.63% to $10.2 billion in 2025, then slumped by 68.13% to $3.3 billion in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $3.3 billion in Q2 2026, $4.5 billion in Q1 2026, and $10.2 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.26 Bn |
| Mar 31, 2026 | 4.52 Bn |
| Dec 31, 2025 | 10.24 Bn |
| Sep 30, 2025 | 4.46 Bn |
| Jun 30, 2025 | 4.04 Bn |
| Mar 31, 2025 | 5.21 Bn |
| Dec 31, 2024 | 11.59 Bn |
| Sep 30, 2024 | 3.59 Bn |
| Jun 30, 2024 | 3.25 Bn |
| Mar 31, 2024 | 3.57 Bn |
| Dec 31, 2023 | 13.40 Bn |
| Sep 30, 2023 | 1.84 Bn |
| Jun 30, 2023 | 2.32 Bn |
| Mar 31, 2023 | 3.03 Bn |
| Dec 31, 2022 | 7.24 Bn |
| Sep 30, 2022 | 2.09 Bn |
| Jun 30, 2022 | 1.69 Bn |
| Mar 31, 2022 | 3.12 Bn |
| Dec 31, 2021 | 17.95 Bn |
| Sep 30, 2021 | 3.70 Bn |